newsfilter
← Latest News
PR Newswire·

BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that Oncurious NV has presented data from a phase I dose escalation ...